

Β

Supplementary Figure 1. Characterisation of iPSC-CMs. A. iPSC-CMs were verified by immunofluorescence staining for Anti-α-Actinin (Sarcomeric), Mouse monoclonal (Sigma, A7732), green. Nuclei counterstained with DAPI (blue). B. Brightfield image of iPSC-CMs. Scale bar = 50µm. Also see uploaded video file of beating iPSC-CMs.



Supplementary Figure 2. Doxorubicin induces CPCs to senescence and D+Q targets senCPCs. A. SA- β -gal quantification of non dox-treated healthy, cycling competent CPCs (hCPCs) and dox-treated senCPCs (sCPCs). B. Crystal violet (viability) quantification of hCPCs and dox-induced sCPCs treated with D+Q. *p<0.0001. C. Representative SA- β -gal staining of senescent CPCs, senenscent CPCs and D+Q and cycling competent, healthy CPCs. D. Representative images for crystal violet staining of senescent CPCs, senenscent CPCs, senenscent



Supplementary Figure 3. Co-culture of adult rat ventricular cardiomyocytes with senCPCs or healthy, cycling competent CPCs. A. Co-culture of adult ventricular rat cardiomyocytes with senCPCs (CM + sCPCs) led to decreased number of crystal violet stained cardiomyocytes, compared to cardiomyocytes co-cultured with healthy, cycling competent CPCs (CTRL CM + hCPCs). Data are Mean \pm SD; n=2. *p=0.007 vs. co-culture CM+hCPCs. **B.** D+Q senolytic treatment of co-cultures of adult ventricular rat cardiomyocytes with senCPCs (CM + sCPCs D+Q), healthy, cycling competent CPCs (CTRL CM + hCPCs D+Q) or cardiomyocyte alone (CTRL CM alone D+Q) showed no differences in crystal violet stained cardiomyocytes between groups. Data are Mean \pm SD; n=2.



Supplementary Figure 4. 24 hours of doxorubicin induced HUVECs into a senescent state 21 days later. SA- β -gal activity in HUVECs before (day 0) and 21 days after doxorubicin treatment. Representative micrograph images of HUVECs stained in enzymatic SA- β -gal assay (right) and in phase contrast (left). Scale bar = 50µm



Supplementary Figure 5. Treatment with senolytics, D+Q, cleared senescent HUVECs. Dox-induced senescent HUVEC viability when treated with 0.5 μ M dasatinib (D) and varying concentrations of quercetin (0.5 - 20 μ M; Q). Data are Mean ± SD, n=2. Representative micrograph images of HUVECs stained with crystal violet. Scale bar = 200 μ M